In India Reversal, 44 Fixed-Dose Combination Drugs To Get June Approval
This article was originally published in PharmAsia News
India's Drug Controller General of India has reversed itself and given approval to 44 of 294 combination drugs it originally rejected as irrational. The fixed-dose combinations include treatments for diarrhea, fever, hypertension and pain. The 44 cleared by the DGCI are expected to be approved in June, subject to the Drug Technical Advisory Board, which is expected to give its final approval soon. (Click here for more
You may also be interested in...
US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.
Fueled by a pipeline of more than 15 biosimilar candidates, Sandoz is aiming to treble the size of its $2bn global biosimilars business by 2030, targeting the US, Europe and Japan. Management spoke at length about the firm’s achievements and prospects during a meeting of parent Novartis’ management.
Rather than hitting the acquisition trial, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.